ArteraAI Announces First-Ever AI-Derived Biomarker for Predicting Androgen Deprivation Therapy (ADT) Benefit in Prostate Cancer

SAN FRANCISCO–(BUSINESS WIRE)–ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced today the publication of data in the NEJM Evidence, validating the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer. The study used novel deep learning methodology and histopathology image data…
Click here to view original post

ADVERTISEMENT — Advertise With Biotech Networks